Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals Incorporated    VRTX

Delayed Quote. Delayed  - 07/29 09:44:17 pm
96.83 USD   +0.64%
07/28DJU.S. HOT STOCKS : Hot Stocks to Watch
07/27DJVERTEX PHARMACE : Pharma Loss Narrows as Cystic Fibrosis Drug Sales ..
07/27 VERTEX PHARMACE : reports 2Q loss
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Vertex Pharmaceuticals Incorporated : VRTX, OSTK, and GRPN added to Nasdaq Gainers Watch List at GSR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/19/2013 | 05:40pm CEST

New York, NY -- (ACCESSWIRE) -- 04/19/2013 -- Growing Stock Report initiates a NASDAQ Gainers Weekly Watch List adding Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Overstock.com Inc. (NASDAQ:OSTK), Groupon, Inc. (NASDAQ:GRPN), BioScrip Inc. (NASDAQ:BIOS) and Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX).

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) a company that engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases is currently up (+55.57%) on 13,455,455 shares traded after announcing statistically significant results from a phase 2 study for the treatment of cystic fibrosis. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is currently up (+134.49%) from its recent 52-week low which has prompted Growing Stock Report to add the stock to their NASDAQ Gainers Watch List.

To see what other Investors are saying about Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=VRTX&SubId=AW

Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) a development-stage specialty pharmaceutical company is currently up (+24.10%) on 1,789,829 shares traded after Coverage was initiated on Catalyst Pharmaceutical by Aegis Capital. Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) is currently up (+105.41%) from its recent 52-week low which has prompted Growing Stock Report to add the stock to their NASDAQ Gainers Watch List.

To see what other Investors are saying about Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=CPRX&SubId=AW

Also mentioned in Growing Stock Report's Nasdaq Gainers Watch List and Investor Poll was: Overstock.com Inc. (NASDAQ:OSTK), Groupon, Inc. (NASDAQ:GRPN), Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) and BioScrip Inc. (NASDAQ:BIOS).

To see what other Investors are saying about: OSTK, GRPN, CPRX and BIOS

Click Here: http://www.growingstockreport.com/PR.aspx?stock=OSTK-GRPN-CPRX-BIOS&SubID=AW

GrowingStockReport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals GrowingStockReport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.GrowingStockReport.com

Disclosure: GrowingStockReport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit GrowingStockReport.com website, for complete risks and disclosures.

Contact Info:
Growing Stock Report
editor@GrowingStockReport.com


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VERTEX PHARMACEUTICALS INC
07/28 VERTEX PHARMACEUTICALS : Researchers Submit Patent Application, "Processes for P..
07/28DJU.S. HOT STOCKS : Hot Stocks to Watch
07/27DJVERTEX PHARMACEUTICALS : Pharma Loss Narrows as Cystic Fibrosis Drug Sales Grow
07/27 VERTEX PHARMACEUTICALS INC / MA : Results of Operations and Financial Condition,..
07/27 VERTEX PHARMACEUTICALS : reports 2Q loss
07/27 VERTEX PHARMACEUTICALS : Reports Second Quarter 2016 Financial Results
07/22 VERTEX PHARMACEUTICALS : Moderna discuss mRNA Therapeutics in cystic fibrosis
07/21 VERTEX PHARMACEUTICALS : to Announce Second Quarter 2016 Financial Results on Ju..
07/14 VERTEX PHARMACEUTICALS : Researchers at Vertex Pharmaceuticals Target Influenza ..
07/14 VERTEX PHARMACEUTICALS : to Announce Second Quarter 2016 Financial Results on Ju..
More news
Sector news : Bio Therapeutic Drugs
02:26pDJMerck Revenue Rises on Cancer, Hepatitis Treatments
02:10pDJMERCK : Revenue Rises on Cancer, Hepatitis Treatments
08:56aDJSanofi Profit Down as Diabetes Drug Sales Slip
07/28DJCELGENE : Lifts Guidance as Revlimid Sales Rise -- Update
07/28DJU.S. HOT STOCKS : Hot Stocks to Watch
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
07/27 Vertex Pharmaceuticals (VRTX) Jeffrey M. Leiden on Q2 2016 Results - Earnings..
07/27 Vertex Pharmaceuticals Incorporated 2016 Q2 - Results - Earnings Call Slides
07/27 Vertex Q2 top line up 160%; non-GAAP EPS up 144%;
07/27 Vertex Pharmaceuticals beats by $0.03, beats on revenue
07/26 Notable earnings after Wednesday?s close
Advertisement
Financials ($)
Sales 2016 1 775 M
EBIT 2016 284 M
Net income 2016 19,9 M
Finance 2016 347 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017 48,48
EV / Sales 2016 13,2x
EV / Sales 2017 9,07x
Capitalization 23 798 M
More Financials
Chart VERTEX PHARMACEUTICALS INC
Duration : Period :
Vertex Pharmaceuticals Inc Technical Analysis Chart | VRTX | US92532F1003 | 4-Traders
Full-screen chart
Technical analysis trends VERTEX PHARMACEUT...
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 110 $
Spread / Average Target 15%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Simon Bedson SVP & GM-International Commercial Operations
Ian F. Smith CFO, EVP & Principal Financial Officer
Jeffrey A. Chodakewitz Chief Medical Officer & Executive Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS..-23.54%23 798
AMGEN, INC.5.51%128 668
GILEAD SCIENCES, INC.-19.72%108 197
CELGENE CORPORATION-7.10%86 182
REGENERON PHARMACEUTIC..-24.28%43 192
ACTELION LTD23.35%19 972
More Results